PT  - JOURNAL ARTICLE
AU  - Sumi, Ayako
TI  - Time series analysis of daily data of COVID-19 reported cases in Japan from January 2020 to February 2023
AID  - 10.1101/2023.04.19.23288796
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.04.19.23288796
4099  - http://medrxiv.org/content/early/2023/04/25/2023.04.19.23288796.short
4100  - http://medrxiv.org/content/early/2023/04/25/2023.04.19.23288796.full
AB  - This study investigatbed temporal variational structures of the COVID-19 pandemic in Japan using a time series analysis incorporating maximum entropy method (MEM) spectral analysis, which produces power spectral densities (PSDs). This method was applied to daily data of COVID-19 cases in Japan from January 2020 to February 2023. The analyses confirmed that the PSDs for data in both the pre- and post-Tokyo Olympics periods show exponential characteristics, which are universally observed in PSDs for time series generated from nonlinear dynamical systems, including the so-called susceptible/exposed/infectious/recovered (SEIR) model, well-established as a mathematical model of temporal variational structures of infectious disease outbreaks. The magnitude of the gradient of exponential PSD for the pre-Olympics period was smaller than that of the post-Olympics period, because of the relatively high complex variations of the data in the pre-Olympics period caused by a deterministic, nonlinear dynamical system and/or undeterministic noise. A 3-dimensional spectral array obtained by segment time series analysis indicates that temporal changes in the periodic structures of the COVID-19 data are already observable before the commencement of the Tokyo Olympics and immediately after the introduction of mass and workplace vaccination programs. Lessons from theoretical studies for measles control programs may be applicable to COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAS Grant Number JP22K10529 JSPS KAKENHI https://www.jsps.go.jp/english/e-grants/ NOAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe dataset of reported COVID-19 cases analyzed during the current study are contained in Supporting information files (S1 Dataset). The data are also available from ref. [12]. https://covid19.mhlw.go.jp/public/opendata/newly_confirmed_cases_daily.csv